Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial

Metastatic Breast ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Locally Recurrent ◽

Faculty of 1000 evaluation for Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717976445.793471388 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments

BMC Cancer ◽

10.1186/1471-2407-13-164 ◽

2013 ◽

Vol 13 (1) ◽

Cited By ~ 15

Author(s):

Lucia Del Mastro ◽

Alessandra Fabi ◽

Mauro Mansutti ◽

Michele De Laurentiis ◽

Antonio Durando ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Trial ◽

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

European Journal of Cancer ◽

10.1016/j.ejca.2014.10.008 ◽

2014 ◽

Vol 50 (18) ◽

pp. 3077-3088 ◽

Cited By ~ 16

Author(s):

S.W. Lam ◽

S.M. de Groot ◽

A.H. Honkoop ◽

A. Jager ◽

A.J. ten Tije ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Locally Recurrent ◽

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)30154-1 ◽

2016 ◽

Vol 17 (9) ◽

pp. 1230-1239 ◽

Cited By ~ 22

Author(s):

Christoph Zielinski ◽

István Láng ◽

Moshe Inbar ◽

Zsuzsanna Kahán ◽

Richard Greil ◽

...

Keyword(s):

Breast Cancer ◽

Primary Endpoint ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

The Lancet Oncology ◽

10.1016/s1470-2045(12)70566-1 ◽

2013 ◽

Vol 14 (2) ◽

pp. 125-133 ◽

Cited By ~ 59

Author(s):

Istvan Lang ◽

Thomas Brodowicz ◽

Larisa Ryvo ◽

Zsuzsanna Kahan ◽

Richard Greil ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

2123 POSTER MO19391: an open-label safety study of bevacizumab plus taxane monotherapy or in combination as first-line treatment of patients with locally recurrent or metastatic breast cancer (LR or MBC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)70885-6 ◽

2007 ◽

Vol 5 (4) ◽

pp. 221 ◽

Cited By ~ 1

Author(s):

I.E. Smith ◽

L. Biganzoli ◽

H. Cortes-Funes ◽

F. Franke ◽

Y. Mostafa Kamel ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Safety Study ◽

Locally Recurrent ◽

MO19391: An open-label safety study of bevacizumab plus taxane-based therapy as first-line treatment of patients with locally recurrent (LR) or metastatic breast cancer (MBC)

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.1140 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 1140-1140 ◽

Cited By ~ 1

Author(s):

J. Pierga ◽

K. I. Pritchard ◽

H. Cortes-Funes ◽

L. Biganzoli ◽

C. Thomssen ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Safety Study ◽

Locally Recurrent ◽

Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials

OncoTargets and Therapy ◽

10.2147/ott.s103954 ◽

2016 ◽

Vol Volume 9 ◽

pp. 3771-3781 ◽

Cited By ~ 3

Author(s):

Xiao-Qun Liu ◽

Xiangdong Liu ◽

Tiankui Qiao ◽

Wei Chen ◽

Sujuan Yuan

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Controlled Trials ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Randomized Controlled ◽

Locally Recurrent ◽

Abstract P1-14-07: Randomized phase 3 study of anthracycline-containing regimens versus S-1 as first-line treatment for metastatic breast cancer (SELECT BC-CONFIRM)–A combined analysis of two randomized phase 3 studies (SELECT BC-CONFIRM and SELECT BC)–

10.1158/1538-7445.sabcs18-p1-14-07 ◽

2019 ◽

Author(s):

Y Park ◽

H Akabane ◽

T Watanabe ◽

M Takahashi ◽

Y Sagara ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Phase 3 ◽

Combined Analysis ◽

Open label, comparative, randomised, multicentre study of trastuzumab given with docetaxel versus sequential single agent therapy with trastuzumab followed by docetaxel as first-line treatment for Her2neu+++ metastatic breast cancer patients

http://isrctn.org/> ◽

10.1186/isrctn13770586 ◽

2012 ◽

Author(s):

J.G.M. Klijn

Keyword(s):

Breast Cancer ◽

Single Agent ◽

Metastatic Breast ◽

Line Treatment ◽

Breast Cancer Patients ◽

First Line ◽

Open Label ◽

Single Agent Therapy ◽